2)、氧合指數(shù)(OI)及動(dòng)脈血/肺泡氣氧分壓比(a/APO2)]及治愈率。結(jié)果 治療后研究組CK、CK-MB、cTnI水平均顯著低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.01)。研究組氧合功能各指標(biāo)均優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。研究組呼吸機(jī)參數(shù)除PEEP外均優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。研究組的用氧天數(shù)、機(jī)械通氣天數(shù)、住院天數(shù)均低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組治愈率相比差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 納洛酮有助于提高NRDS整體療效,對(duì)NRDS心肌保護(hù)作用明顯。;Objection To investigate the clinical efficacy and myocardial protection of naloxone in the treatment of neonatal respiratory distress syndrome (NRDS).Methods 100 patients who suffer from NRDS were randomly divided into the study group (50 cases) and the control group (50 cases). The control group were given conventional treatment while the study group was additionally treated with naloxone. Before and after the study, their serum levels of CK, CK-MB, cTnI were compared between the two groups. The following parameters (days in hospital, duration time of ventilation, oxygenation function (PaO2、OI and a/APO2), cure rate) alse compared between the two groups.Results The serum level of CK, CK-MB, cTnI in the study group were obviously lower than the control group. The oxygenation function of the study group was superior to the control group (P< 0.05). The ventilation function of the study group was better than the control group except PEEP. After treatment, the days in hospital, the duration time of ventilation and the oxygen days were better than the control group (P< 0.05). There was no significant statistical difference between the two groups in the cure rate.Conclusion Naloxone can protect myocardial and improve the effectiveness on the conventional treatment in the NRDS."/>

久久久久亚洲精品,久久无码av三级,娇妻借朋友高h繁交h,久久男人av资源站,狠狠久久五月精品中文字幕

首頁(yè) > 過(guò)刊瀏覽>2018年第41卷第2期 >2018,41(2):255-258. DOI:10.7501/j.issn.1674-6376.2018.02.016
上一篇 | 下一篇

納洛酮治療急性新生兒呼吸窘迫綜合征的臨床療效及其心肌保護(hù)作用

Clinical efficacy and myocardial protection of naloxone in the treatment of neonatal respiratory distress syndrome (NRDS)

發(fā)布日期:2018-03-17
您是第位訪問(wèn)者
藥物評(píng)價(jià)研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號(hào) 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書(shū)編號(hào):(津)-非經(jīng)營(yíng)性-2015-0031